ALEC Alector Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ALEC

Price (delayed)

$2.06

Market cap

$228.71M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.19

Enterprise value

$184.45M

?
Relative Growth: Rel. Growth: 12
Relative Strength: Rel. Strength: 38
Relative Valuation: Rel. Valuation: 9
Relative Profitability: Rel. Profitability: 29

Alector is a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. The Company is developing a broad portfolio of innate immune system ...

Highlights
The quick ratio has soared by 57% YoY and by 37% from the previous quarter
The debt has contracted by 16% YoY and by 4.7% from the previous quarter
The equity has shrunk by 89% YoY and by 66% QoQ
ALEC's gross profit has plunged by 79% YoY and by 12% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://alector.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of ALEC

ALEC stock price

How has the Alector stock price performed over time
Intraday
2.49%
1 week
11.35%
1 month
5.64%
1 year
37.33%
YTD
32.05%
QTD
2.49%

Financial performance

How have Alector's revenue and profit performed over time
Revenue
$18.42M
Gross profit
$18.42M
Operating income
-$136.23M
Net income
-$125.39M
Gross margin
100%
Net margin
-680.8%
ALEC's gross profit has plunged by 79% YoY and by 12% from the previous quarter
The revenue has dropped by 79% year-on-year and by 12% since the previous quarter
ALEC's operating income is up by 13% since the previous quarter and by 7% year-on-year
Alector's net income has increased by 12% QoQ

Price vs fundamentals

How does ALEC's price correlate with its fundamentals

Growth

What is Alector's growth rate over time

Valuation

What is Alector stock price valuation
P/E
N/A
P/B
21.9
P/S
12.37
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10.02
ALEC's EPS is up by 14% from the previous quarter and by 4.8% YoY
ALEC's P/B is 146% above its last 4 quarters average of 8.9
The equity has shrunk by 89% YoY and by 66% QoQ
The stock's price to sales (P/S) is 113% more than its 5-year quarterly average of 5.8 and 85% more than its last 4 quarters average of 6.7
The revenue has dropped by 79% year-on-year and by 12% since the previous quarter

Efficiency

How efficient is Alector business performance
The return on equity has dropped by 193% year-on-year and by 31% since the previous quarter
The return on invested capital has dropped by 76% year-on-year and by 3.1% since the previous quarter
Alector's ROA has plunged by 63% YoY

Dividends

What is ALEC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ALEC.

Financial health

How did Alector financials performed over time
ALEC's total assets is 4.5% greater than its total liabilities
Alector's current ratio has soared by 57% YoY and by 37% from the previous quarter
The quick ratio has soared by 57% YoY and by 37% from the previous quarter
The debt to equity has soared by 182% since the previous quarter
The equity has shrunk by 89% YoY and by 66% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.